Inside information: Nanoform announces new midterm business targets for 2030

• 3 Nanoformed medicines launched by 2030

• Income* growth >50% CAGR** 2026-2030

• EBIT margin >30% by 2030

*Revenue + other operating income (milestones, fees, royalties, profit shares etc.)
**Compound annual growth rate

Since the IPO in 2020, Nanoform have scaled up two technologies, built two dozen R&D lines, several cleanrooms and GMP lines, GMP Quality Control labs, and added formulation expertise to its offering. We have built first a paper-based quality management system and then digitized it, implemented SAP, SCADA, Trackwise Digital eQMS, Workiva, scaled up and taught our AI engine STARMAP^® to be fast and accurate. We received a single-API clinical license followed by a multi-API commercial license, enabled and sponsored several clinical trials and manufactured their materials. We filed and won several new patents and secured over 50 new clients across three continents, including 12 of the world’s top 20 pharmaceutical companies, while successfully delivering more than 100 customer projects. During (2020-2025) our annual income grew ~45% CAGR while the number of projects run in parallel grew from a few to a few dozen.

During the next five years Nanoform will launch several nanoformed small molecule based products together with partners onto the global markets, the income is expected to grow at >50% CAGR per year, while the costs are expected to grow <5% CAGR per year, leading at the end of 2030 to an EBIT margin >30%. On the biologics side, the main focus is to get GMP capabilities and enable multiple customers’ clinical trials, paving the way for nanoforming to become a significant technology in the major industrial shift from intravenous delivery to subcutaneous delivery of biologicals.

Edward Hæggström, Chief Executive Officer, commented:

“Today we announced our strategy for the next 5-years, where we aim to breach ‘The Wall’ in both small molecules and biologics. On the small molecules side, we target to have several Nanoformed medicines in pharmacies globally within 5 years, while on the biologics side we target clinical data with multiple customers supporting nanoforming as a significant technology in the major industrial shift from intravenous delivery to subcutaneous delivery of biologics”.

Nanoform hosts its in-person Capital Markets Day (CMD) Tuesday, December 16^th, 2025, in Helsinki at Nanoform’s headquarters and commercial cGMP manufacturing site.

CMD presentation materials can be found on www.nanoform.com/en/investors/capital-markets-day-2025/. A transcript will be published on the same website after the event.

For further information, please contact:
Albert Hæggström, CFO
[email protected] 
+358 (0)40 161 4191

Henri von Haartman, IR
[email protected]
+46 (0)7686 650 11

The information provided in this stock exchange release was submitted for publication, through the agency of the contacts set out above, at 07.00 EET (06.00 CET) on December 16^th, 2025.

About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services, from pre-clinical to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: DNB Carnegie Investment Bank AB, +46 8 588 685 70, [email protected]. For more information, please visit www.nanoform.com. 

Nanoform forward-looking statements 
This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform’s strategy, business plans and focus. The words “may”, “will”, “could”, “would”, “should”, “expect”, “plan”, “anticipate”, “intend”, “believe”, “estimate”, “predict”, “project”, “potential”, “continue”, “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Nanoform’s business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks described in the Report of the Board of Directors and Financial Statements for the year ended December 31, 2024 as well as our other past disclosures. Nanoform cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nanoform disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Nanoform’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.